Article
Biochemistry & Molecular Biology
Nabil F. Saba, Conor E. Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca, Mihir Patel, Nicole C. Schmitt, William Stokes, James E. Bates, Soumon Rudra, Jill Remick, Mark McDonald, Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah, Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen, Dong M. Shin, Yong Teng, Christine H. Chung
Summary: PD-1 therapy is standard treatment for recurrent metastatic head and neck squamous cell carcinoma. The combination of Pembrolizumab and Cabozantinib shows promising clinical activity. Further research is needed.
Article
Oncology
Rodrigo R. Munhoz, Guilherme Nader-Marta, Veridiana P. de Camargo, Marcello M. Queiroz, Jade Cury-Martins, Herminia Ricci, Marcela R. de Mattos, Thiago A. F. de Menezes, Guilherme U. C. Machado, Eduardo Bertolli, Milton Barros, Carina E. de Souza, Fabio Franke, Fabio O. Ferreira, Olavo Feher, Gilberto de Castro Jr
Summary: The study investigated the activity of the anti-PD-1 agent nivolumab in patients with advanced CSCC and found robust antitumor activity, sustained responses, and good tolerability. These results provide further evidence to support the use of immune checkpoint inhibition as the standard treatment of advanced CSCC.
Article
Urology & Nephrology
Arlene O. Siefker-Radtke, Daniel C. Cho, Adi Diab, Mario Sznol, Mehmet A. Bilen, Arjun Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhury, Danni Yu, Sue L. Currie, Mary A. Tagliaferri, Jonathan Zalevsky, Michael E. Hurwitz, Nizar M. Tannir
Summary: The study evaluated the effectiveness of the immunostimulatory cytokine prodrug BEMPEG plus nivolumab as a first-line treatment for advanced/metastatic urothelial carcinoma patients, showing that the combination was well-tolerated and demonstrated good antitumor activity.
Article
Oncology
Michael Staehler, Michael Stoeckle, Daniel C. Christoph, Arnulf Stenzl, Karin Potthoff, Marc-Oliver Grimm, Dunja Klein, Johanna Harde, Fabian Bruning, Peter J. Goebell, Marinela Augustin, Frederik Roos, Iris Benz-Rud, Norbert Marschner, Viktor Gruenwald
Summary: The MARC-2 trial investigated clinical outcomes in metastatic renal cell carcinoma patients treated with everolimus after failure of VEGFR-TKI therapy, finding that patients aged >=65 years and patients with BMI >25 kg/m2 benefited most, with no new safety signals emerging.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano, Toshimi Takano
Summary: This study investigated the use of nivolumab, bevacizumab, and paclitaxel triple therapy for metastatic breast cancer. The results showed promising efficacy and manageable toxicity of this treatment in the first-line setting.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Urology & Nephrology
Jean Courcier, Cecile Dalban, Brigitte Laguerre, Sylvain Ladoire, Philippe Barthelemy, Stephane Oudard, Florence Joly, Gwenaelle Gravis, Christine Chevreau, Lionel Geoffrois, Elise Deluche, Frederic Rolland, Delphine Topart, Stephane Culine, Sylvie Negrier, Hakim Mahammedi, Florence Tantot, Antoine Jamet, Bernard Escudier, Ronan Flippot, Laurence Albiges
Summary: In patients who did not undergo upfront cytoreductive nephrectomy, nivolumab showed limited activity against the primary tumor, with most patients at intermediate or poor risk and only a small proportion experiencing tumor shrinkage.
Article
Biochemistry & Molecular Biology
Priscilla K. K. Brastianos, Albert E. E. Kim, Anita Giobbie-Hurder, Eudocia Q. Q. Lee, Nancy U. U. Lin, Beth Overmoyer, Patrick Y. Y. Wen, Lakshmi Nayak, Justine V. V. Cohen, Jorg Dietrich, April Eichler, Rebecca S. S. Heist, Ian Krop, Donald Lawrence, Jennifer Ligibel, Sara Tolaney, Erica Mayer, Eric Winer, Brittany Bent, Magali A. A. de Sauvage, Nazanin Ijad, Juliana M. M. Larson, Braxton Marion, Sally Nason, Naina Murthy, Sherry Ratcliff, Elizabeth J. J. Summers, Maura Mahar, Helen A. A. Shih, Kevin Oh, Daniel P. P. Cahill, Elizabeth R. R. Gerstner, Ryan J. J. Sullivan
Summary: In a clinical trial, pembrolizumab was found to be effective in treating patients with untreated and recurrent brain metastases, with some patients achieving a survival of over 2 years. However, the treatment also carried the risk of adverse events.
Article
Oncology
Meredith S. Pelster, Stephen K. Gruschkus, Roland Bassett, Dan S. Gombos, Michael Shephard, Liberty Posada, Maura S. Glover, Rinata Simien, Adi Diab, Patrick Hwu, Brett W. Carter, Sapna P. Patel
Summary: The combination regimen of nivolumab plus ipilimumab shows activity in metastatic uveal melanoma, yielding deep and sustained confirmed responses.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Surgery
Jesse E. Passman, Wajid Amjad, Sara P. Ginzberg, Jacqueline M. Soegaard Ballester, Caitlin Finn, Heather Wachtel
Summary: This study evaluated the impact of primary tumor resection and metastasectomy on the survival of patients with metastatic ACC. The results showed that primary tumor resection alone and combined resection with metastasectomy were significantly associated with improved overall survival, while metastasectomy alone had no survival benefit. These findings provide guidance for surgical treatment decisions in patients with metastatic ACC.
WORLD JOURNAL OF SURGERY
(2023)
Article
Biochemistry & Molecular Biology
Ari VanderWalde, Shay L. Bellasea, Kari L. Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, Frances Collichio, Jeffrey A. Sosman, Alexandra Ikeguchi, Adrienne I. Victor, Thach-Giao Truong, Bartosz Chmielowski, David C. Portnoy, Yuanbin Chen, Kim Margolin, Charles Bane, Constantin A. Dasanu, Douglas B. Johnson, Zeynep Eroglu, Sunandana Chandra, Egmidio Medina, Cynthia R. Gonzalez, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Ivan Perez Garcilazo, Elad Sharon, Siwen Hu-Lieskovan, Sapna P. Patel, Kenneth F. Grossmann, James Moon, Michael C. Wu, Antoni Ribas
Summary: In this randomized phase 2 trial, combination therapy of ipilimumab and nivolumab showed significant improvement in progression-free survival in patients with metastatic melanoma compared to ipilimumab alone. However, the impact on CD8 T cell infiltrate in tumor was not statistically significant.
Article
Multidisciplinary Sciences
Takuma Matoba, Kiyoshi Minohara, Daisuke Kawakita, Gaku Takano, Keisuke Oguri, Akihiro Murashima, Kazuyuki Nakai, Sho Iwaki, Hiroshi Tsuge, Nobukazu Tanaka, Sae Imaizumi, Wataru Hojo, Ayano Matsumura, Koji Tsukamoto, Shinichi Esaki, Shinichi Iwasaki
Summary: Tumor burden is an important prognostic factor for patients with recurrent or metastatic head and neck cancer receiving immune checkpoint inhibitors (ICIs). The baseline number of metastatic lesions (BNML) and the baseline sum of the longest diameters of the target lesions (BSLD) can be used to evaluate tumor burden. Additionally, higher standardized uptake value (SUVmax) is associated with worse overall survival and progression-free survival. Therefore, imaging examinations before ICI treatment are recommended to predict treatment efficacy.
SCIENTIFIC REPORTS
(2022)
Article
Endocrinology & Metabolism
Alice Boileve, Elise Mathy, Charles Roux, Matthieu Faron, Julien Hadoux, Lambros Tselikas, Abir Al Ghuzlan, Segolene Hescot, Sophie Leboulleux, Thierry de Baere, Livia Lamartina, Frederic Deschamps, Eric Baudin
Summary: This study aimed to evaluate the therapeutic strategy of locoregional treatments (LRT) combined with mitotane in patients with low tumor burden stage IVA adrenocortical carcinoma (ACC). The results suggest that the combination of LRT and mitotane can improve progression-free survival (PFS) and overall survival (OS) in this selected group of patients with ACC. The study also observed a significant number of complete responses in patients receiving mitotane plus LRT, highlighting the potential benefits of this treatment approach.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Oncology
Laurence Albiges, Aude Flechon, Christine Chevreau, Delphine Topart, Gwenaelle Gravis, Stephane Oudard, Jean M. Tourani, Lionnel Geoffrois, Emeline Meriaux, Antoine Thiery-Vuillemin, Philippe Barthelemy, Sylvain Ladoire, Brigitte Laguerre, Valerie Perrot, Anais Billard, Bernard Escudier, Marine Gross-Goupil
Summary: The study reports treatment patterns and outcomes for patients with mRCC who received cabozantinib through the French Early Access Program. Cabozantinib showed effectiveness in unselected, heavily pretreated mRCC patients, with initiation at 60 mg/day associated with improved outcomes.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Jesse E. Passman, Wajid Amjad, Jacqueline M. Soegaard Ballester, Sara P. Ginzberg, Heather Wachtel
Summary: Age, disease stage, surgical approach, and surgical margins are key factors affecting survival in patients with non-metastatic ACC. The extent of surgery and lymphadenectomy are not related to overall survival. In advanced disease, the open surgical approach is associated with improved survival.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Emre Yekeduz, Ismail Erturk, Deniz Tural, Nuri Karadurmus, Serdar Karakaya, Mutlu Hizal, Rukiye Arikan, Cagatay Arslan, Hakan Taban, Ahmet Kucukarda, Nihan Senturk oztas, ozlem Nuray Sever, Gokhan Ucar, Orcun Can, Mehmet Ali Nahit Sendur, Umut Demirci, Saadettin Kilickap, Irfan Cicin, Berna Oksuzoglu, Mustafa ozguroglu, Yuksel Urun
Summary: The study presented real-world data on the efficacy and safety of nivolumab in 173 patients with mRCC, showing that nivolumab was effective in these patients without any new safety concerns.
Article
Oncology
Benedito A. Carneiro, Sahithi Pamarthy, Ami N. Shah, Vinay Sagar, Kenji Unno, HuiYing Han, Ximing J. Yang, Rubens B. Costa, Rebecca J. Nagy, Richard B. Lanman, Timothy M. Kuzel, Jeffrey S. Ross, Laurie Gay, Julia A. Elvin, Siraj M. Ali, Massimo Cristofanilli, Young K. Chae, Francis J. Giles, Sarki A. Abdulkadir
CLINICAL CANCER RESEARCH
(2018)
Meeting Abstract
Oncology
Rajita Vatapalli, Yara Rodriguez, Changsheng Zhao, Vinay Sagar, Jonathan Anker, Sahithi Pamarthi, Kenji Unno, Benedito Carneiro, Debabrata Chakravarti, Sarki Abdulkadir
Article
Oncology
Huiying Han, Atul D. Jain, Mihai I. Truica, Javier Izquierdo-Ferrer, Jonathan F. Anker, Barbara Lysy, Vinay Sagar, Yi Luan, Zachary R. Chalmers, Kenji Unno, Hanlin Mok, Rajita Vatapalli, Young A. Yoo, Yara Rodriguez, Irawati Kandela, J. Brandon Parker, Debabrata Chakravarti, Rama K. Mishra, Gary E. Schiltz, Sarki A. Abdulkadir
Article
Cell Biology
Vinay Sagar, Rajita Vatapalli, Barbara Lysy, Sahithi Pamarthy, Jonathan F. Anker, Yara Rodriguez, Huiying Han, Kenji Unno, Walter M. Stadler, William J. Catalona, Maha Hussain, Parkash S. Gill, Sarki A. Abdulkadir
CELL DEATH & DISEASE
(2019)
Article
Multidisciplinary Sciences
R. Vatapalli, V. Sagar, Y. Rodriguez, J. C. Zhao, K. Unno, S. Pamarthy, B. Lysy, J. Anker, H. Han, Y. A. Yoo, M. Truica, Z. R. Chalmers, F. Giles, J. Yu, D. Chakravarti, B. Carneiro, S. A. Abdulkadir
NATURE COMMUNICATIONS
(2020)
Article
Oncology
Kenji Unno, Zachary R. Chalmers, Sahithi Pamarthy, Rajita Vatapalli, Yara Rodriguez, Barbara Lysy, Hanlin Mok, Vinay Sagar, Huiying Han, Young A. Yoo, Sheng-Yu Ku, Himisha Beltran, Yue Zhao, Sarki A. Abdulkadir
Summary: The coactivation of ALK and N-Myc induces NEPC through stimulation of the Wnt/beta-catenin pathway. Inhibition of ALK and Wnt pathways represents a potential therapeutic strategy for NEPC and neuroblastoma.
Article
Oncology
Anuj S. Desai, Vinay Sagar, Barbara Lysy, Adam B. Weiner, Oliver S. Ko, Conor Driscoll, Yara Rodriguez, Rajita Vatapalli, Kenji Unno, Huiying Han, Jason E. Cohen, Amanda X. Vo, Minh Pham, Michael Shin, Ketan Jain-Poster, Jennifer Ross, Elizabeth G. Morency, Travis J. Meyers, John S. Witte, Jennifer Wu, Sarki A. Abdulkadir, Shilajit D. Kundu
Summary: The study found that men with IBD had a higher proportion of T and B lymphocyte infiltration in prostate tumors. Mouse models showed that chronic colitis can be transferred to the wild-type mouse prostate, causing abnormal levels of pro-inflammatory cytokines and oncogenic signaling activation.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Oncology
Yara Rodriguez, Kenji Unno, Mihai I. Truica, Zachary R. Chalmers, Young A. Yoo, Rajita Vatapalli, Vinay Sagar, Jindan Yu, Barbara Lysy, Maha Hussain, Huiying Han, Sarki A. Abdulkadir
Summary: This study identifies PRRX2 as a driver of enzalutamide resistance in prostate cancer. PRRX2 expression is highest in double-negative prostate cancer cases and its associated gene signature can serve as a biomarker for enzalutamide resistance, which can be reversed with CDK4/6 and BCL2 inhibitors.
Article
Multidisciplinary Sciences
Austin G. Holmes, J. Brandon Parker, Vinay Sagar, Mihai Truica, Pritin N. Soni, Huiying Han, Gary E. Schiltz, Sarki A. Abdulkadir, Debabrata Chakravarti
Summary: The MYCi975 inhibitor selectively inhibits MYC target gene expression and alters MYC chromatin binding, suppressing proliferation and differentiation in specific tumor cells. Additionally, MYCi975 enhances the sensitivity of hormone therapy resistant tumor cells.
Article
Oncology
David J. VanderWeele, Masha Kocherginsky, Sabah Munir, Brenda Martone, Vinay Sagar, Alicia Morgans, Walter M. Stadler, Sarki Abdulkadir, Maha Hussain
Summary: Blocking the EphB4-EphrinB2 pathway with sEphB4-HSA monotherapy showed no anti-tumor activity in patients with mCRPC.
CLINICAL GENITOURINARY CANCER
(2022)
Meeting Abstract
Oncology
Michael C. Burns, Vinay Sagar, Borko Jovanovic, Alicia K. Morgans, David James VanderWeele, David I. Quinn, Walter Michael Stadler, Sarki Abdulkadir, Maha H. A. Hussain
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Meeting Abstract
Urology & Nephrology
Anuj Desai, Barbara Lysy, Vinay Sagar, Rajita J. Vatapalli, HuiYing Han, Kenji Unno, Yara R. Rodriguez, Conor Driscoll, Jenny Ross, Jennifer D. Wu, Sarki A. Abdulkadir, Shilajit Kundu
JOURNAL OF UROLOGY
(2020)
Article
Oncology
Benedito A. Carneiro, Katharine Ann Collier, Rebecca J. Nagy, Sahithi Pamarthy, Vinay Sagar, Stephen Fairclough, Justin Odegaard, Richard B. Lanman, Ricardo Costa, Timothy Taxter, Timothy M. Kuzel, Alice Fan, Young Kwang Chae, Massimo Cristofanilli, Maha H. Hussain, Sarki A. Abdulkadir, Francis J. Giles
JCO PRECISION ONCOLOGY
(2018)
Meeting Abstract
Oncology
Sahithi Pamarthy, Vinay Sagar, Rajita J. Vatapalli, Zachary Reinstein, Muhammad Zayd Ansari, Benedito A. Carneiro Filho, Francis J. Giles, Sarki A. Abdulkadir